Difference between revisions of "Copanlisib (Aliqopa)"
Jump to navigation
Jump to search
m |
m |
||
| Line 5: | Line 5: | ||
===[[Follicular lymphoma]]=== | ===[[Follicular lymphoma]]=== | ||
# '''Abstract:''' Martin H. Dreyling, Armando Santoro, Sirpa Leppa, Judit Demeter, George Follows, Georg Lenz, Won Seog Kim, Luigina Mollica, Arnon Nagler, Colin Phipps Diong, Mariano Provencio, Don A. Stevens, David Trevarthen, Massimo Magagnoli, Lisa Cupit, Shuxin Yin, Florian Hiemeyer, Jose E. Garcia-Vargas, Barrett H. Childs, and Pier Luigi Zinzani. Copanlisib in patients with relapsed or refractory follicular lymphoma. Journal of Clinical Oncology 2017 35:15_suppl, 7535-7535 [http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.7535 link to abstract] | # '''Abstract:''' Martin H. Dreyling, Armando Santoro, Sirpa Leppa, Judit Demeter, George Follows, Georg Lenz, Won Seog Kim, Luigina Mollica, Arnon Nagler, Colin Phipps Diong, Mariano Provencio, Don A. Stevens, David Trevarthen, Massimo Magagnoli, Lisa Cupit, Shuxin Yin, Florian Hiemeyer, Jose E. Garcia-Vargas, Barrett H. Childs, and Pier Luigi Zinzani. Copanlisib in patients with relapsed or refractory follicular lymphoma. Journal of Clinical Oncology 2017 35:15_suppl, 7535-7535 [http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.7535 link to abstract] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *9/14/2017: Granted FDA accelerated approval "for the treatment of adult patients with relapsed [[follicular lymphoma]] who have received at least two prior systemic therapies." | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' BAY 80-6946 | ||
| + | *'''Brand name:''' Aliqopa | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | [[Category: | + | [[Category:Intravenous medications]] |
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
| Line 14: | Line 21: | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| − | [[Category: | + | [[Category:Drugs FDA approved in 2017]] |
Revision as of 18:35, 14 September 2017
Mechanism of action
From NCI Drug Dictionary: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.
Preliminary data
Follicular lymphoma
- Abstract: Martin H. Dreyling, Armando Santoro, Sirpa Leppa, Judit Demeter, George Follows, Georg Lenz, Won Seog Kim, Luigina Mollica, Arnon Nagler, Colin Phipps Diong, Mariano Provencio, Don A. Stevens, David Trevarthen, Massimo Magagnoli, Lisa Cupit, Shuxin Yin, Florian Hiemeyer, Jose E. Garcia-Vargas, Barrett H. Childs, and Pier Luigi Zinzani. Copanlisib in patients with relapsed or refractory follicular lymphoma. Journal of Clinical Oncology 2017 35:15_suppl, 7535-7535 link to abstract
History of changes in FDA indication
- 9/14/2017: Granted FDA accelerated approval "for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies."
Also known as
- Code name: BAY 80-6946
- Brand name: Aliqopa